GTx GTXI 深 滬
等待開盤 10-07 09:30:00 美东时间
1.20
0.000
0.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 1.20
- 總市值 2199.00万
- 52周最高 358.40
- 市盈率 靜 --
- 換手率 0.00%
- 52周最低 24.00
- 委 比 0.00%
- 總股本 1832.50万
- 歷史最高 10136.00
- 量 比 0
- 振 幅 0.00%
- 歷史最低 24.00
- 每 手 1
- 風險率 0.00%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Grace Therapeutics Secures New Patent for GTx-104
An update from Grace Therapeutics ( ($GRCE) ) is now available. On September 18...
09-18 20:58
Grace Therapeutics Awarded Patent Titled "Nimodipine Parenteral Administration" From U.S. Patent and Trademark Office. Patent Covers Dosing Regimen For Intravenous Nimodipine Used In Phase 3 Strive-On Safety Trial For GTX-104
Grace Therapeutics, Inc. (NASDAQ:GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for I.V.
09-18 20:38
FDA Accepts Grace Therapeutics’ NDA for GTx-104
Grace Therapeutics ( ($GRCE) ) has issued an update. On August 22, 2025, the FD...
08-27 20:29
FDA Accepts Grace Therapeutics' New Drug Administration For GTx-104 For Formal Review
FDA Establishes April 23, 2026 as PDUFA Target Date for Review of Submission Seeking Approval for GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH)Comprehensive Data Package Supported by
08-27 20:03
基因疗法“一劳永逸”?跨国药企争抢布局：罗氏、诺华、渤健……
（来源：动脉新医药） 近年来，以AAV为主流载体的基因疗法凭借其“一劳永逸”的独特优势，让全球生物医药企业玩家争抢着上牌桌。 从耳朵到大脑、从眼睛...
08-18 18:18
Chardan Capital Maintains Buy on MeiraGTx Hldgs, Maintains $35 Price Target
Chardan Capital analyst Daniil Gataulin maintains MeiraGTx Hldgs (NASDAQ:MGTX) with a Buy and maintains $35 price target.
08-15 19:29
MeiraGTx Reports Progress in Genetic Medicines Development
Meiragtx Holdings ( ($MGTX) ) has released its Q2 earnings. Here is a breakdown...
08-15 12:28
MeiraGTx Hldgs Q2 EPS $(0.48) Misses $(0.46) Estimate, Sales $3.691M Miss $8.003M Estimate
MeiraGTx Hldgs (NASDAQ:MGTX) reported quarterly losses of $(0.48) per share which missed the analyst consensus estimate of $(0.46) by 5.03 percent. This is a 36.84 percent increase over losses of $(0.76) per share from
08-14 20:06
A Look Ahead: Stoke Therapeutics's Earnings Forecast
Stoke Therapeutics (NASDAQ:STOK) is preparing to release its quarterly earnings...
08-12 00:03
MeiraGTx Gains UK Approval for Hologen Transactions
Meiragtx Holdings ( ($MGTX) ) has issued an announcement. MeiraGTx Holdings plc...
06-26 20:29
